Stocks · News reference

Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.

Jul 27, 2026, 2:19 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 2:03 PMAvi Kapoor
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Read original at benzinga
ABCL CAPR CDLR CRML EIKN
BenzingaAug 19, 2026, 2:08 PMAvi Kapoor
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
Read original at benzinga
ARIS ASTL BNTX COTY CRSP
BenzingaAug 14, 2026, 1:21 PMBenzinga Newsdesk
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.
Read original at benzinga
EIKN
SEC EDGARAug 14, 2026, 12:44 AMSEC EDGAR
8-K filing — Eikon Therapeutics, Inc. (EIKN)
Filed: 2026-08-14 AccNo: 0001193125-26-349936 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
EIKN